Feature
Video
AUA 2024: Dr. Smelser recaps key bladder cancer research
Author(s):
Woodson W. Smelser, MD, discusses key bladder cancer data that was presented at the 2024 AUA Annual Meeting.
In this interview, Woodson W. Smelser, MD, discusses key bladder cancer data that was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Smelser is an assistant professor of surgery at Washington University School of Medicine in St. Louis, Missouri.
During the discussion, Smelser highlights the following abstracts:
1. P2-01: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study
2. P2-02: Pivotal results from BOND-003: A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
3. P2-08: LEGEND: a phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)
4. PD48-01: Efficacy of Nadofaragene Firadenovec-vncg for Patients With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Final Results From a Phase 3 Trial
5. PD34-10: First results of NURE-Combo: a phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC)
